Alzheimer disease trials in Japan

In Japan 21 Also abroad 815

21 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Where
Bunkyo-ku, Fukuoka, Hadano, Kanzaki-Gun Yoshinogari-Cho, Karatsu-shi, Kawasaki, Okayama, Sakai, Shimotsuke-shi, Tochigi
Age
55 years to 90 years
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011732 · EU 2025-520613-31-00
Phase 3Taking people
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Where
Aichi, Hyōgo, Tokyo
Age
55 years to 80 years
People
1,600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07717411
Phase 1Taking people
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
Where
Bunkyō City, Ōbu
Age
18 years to 85 years
People
179 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07787169
Phase 2Taking people
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Where
Bunkyō City, Fujisawa, Himeji, Inage, Kawasaki, Kobe, Kōtoku, Kurashiki, Nagoya, Ōbu, Suita, tabashi City, Tachikawa, Toride, Yokohama, Yufu
Age
55 years to 85 years
People
350 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07589595
Phase 1Taking people
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Where
Bunkyō City
Age
50 years to 85 years
People
56 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06297590 · EU 2024-510604-37-00
Phase 3Taking people
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Where
Chūōku, Hachiōji, Ōbu, Shinjuku, Shinjyuku, tabashi City
Age
55 years and over
People
550 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07602582
Phase 3Taking people
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Where
Fukuoka, Hachiōji, Hadano, Himeji-Shi, Hiroshima, Iizuka, Kanzaki-Gun Yoshinogari-Cho, Kawasaki-Shi, Kōriyama, Kumamoto, Kyoto, Sakai, Sapporo, Setagaya-Ku, Takamatsu, Takatsuki, Tatebayashi, Toride-shi, Tsu, Wako-Shi, Yokohama, Yoshinogawa
Age
55 years to 90 years
People
406 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00
Phase 1Taking people
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
Where
Bunkyō City, Ōbu
Age
18 years to 85 years
People
68 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07787182 · EU 2026-527295-81-00
No phaseTaking people
REXULTI General Use Results Survey in Patients With Hyperactivity, or Aggressive Behavior Associated With Alzheimer's Dementia
Where
Osaka
Age
15 years and over
People
200
Run by
Otsuka Pharmaceutical Co., Ltd.
See details and how to joinNCT06875986
Phase 2Taking people
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Where
Chiba, Fukuoka, Hirakata, Kanzaki-gun, Kawasaki, Kurashiki, Narashino, Ōbu, Okayama, Shinjuku, Tsu
Age
50 years to 85 years
People
340 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07033494 · EU 2024-519190-19-00
Phase 3Taking people
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Where
Aichi, Hiroshima, Hyōgo, Kagawa, Kanagawa, Kochi, Kyoto, Meguro-Ku, Mie, Okayama, Osaka, Tokyo, Yamagata
Age
50 years to 90 years
People
80,000 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07177352
Phase 3Taking people
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Where
Hachiōji, Hadano, Himeji-Shi, Hiroshima, Iizuka, Kawasaki-Shi, Kōriyama, Kumamoto, Kyoto, Sakai, Sapporo, Setagaya-Ku, tabashi City, Takamatsu, Takatsuki, Tatebayashi, Toride-shi, Tsu, Yokohama, Yoshinogawa
Age
55 years to 90 years
People
1,000 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00
Phase 3Taking people
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Where
Bunkyo-ku, Fukuoka, Hadano, Kanzaki-Gun Yoshinogari-Cho, Karatsu-shi, Kawasaki, Okayama, Sakai, Shimotsuke-shi, Tochigi
Age
55 years to 90 years
People
650 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Where
Hirakata, Hiroshima, Ina, Inage, Kamakura, Kashiwazaki, Kawasaki, Kita-gun, Kurashiki, Kyoto, Matsudo, Osaka, Wako, Yoshinogari-cho, Kanzaki-gun
Age
60 years to 85 years
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976203 · EU 2025-520747-32-00
Phase 1Not yet taking people in Japan
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
Where
Bunkyō City, Ōbu
Age
18 years to 85 years
People
111 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07843459
No phaseTaking people
Dominantly Inherited Alzheimer Network (DIAN)
Where
Niigata, Osaka, Tokyo
Age
18 years and over
People
700 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT00869817
Phase 2Taking people
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
Where
Aichi, Akita, Aomori, Fukui, Fukuoka, Gunma, Hiroshima, Hokkaido, Kagoshima, Kanagawa, Kochi, Kyoto, Miyagi, Nagano, Nara, Osaka, Saga, Saitama, Tokyo, Yamagata
Age
55 years to 90 years
People
90
Run by
Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT06803823
Phase 3Taking people
Epidemiology and Biomarker Study in Alzheimer's Disease
Where
Bunkyō City, Tokyo
Age
55 years to 75 years
People
3,400 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07142954
Phase 3Taking people
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Where
Nankoku-shi, Osaka, Suita
Age
55 years to 90 years
People
325 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06947941
Phase 1Taking people
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
Where
Bunkyō City, Ōbu
Age
45 years to 85 years
People
128 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06657768
No phaseTaking people
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
Where
Hiroshima, Kyoto, Tokyo
Age
18 years and over
People
5,000
Run by
Eisai Co., Ltd.
See details and how to joinNCT06322667